Vaccines against cholera, typhoid fever and shigellosis for developing countries

Expert Opinion on Biological Therapy

Volumn 4, Issue 12, 2004, Pages 1939-1951

  Acosta, C J ^a   Galindo, C M ^a   Deen, J L ^a   Ochiai, R L ^a   Lee, H J ^a   Von Seidlein, L ^a   Carbis, R ^a   Clemens, J D ^a,b  

^a Seoul National University   (South Korea)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Cholera; Developing countries; Enteric diseases; Shigellosis; Typhoid fever; Vaccines

Indexed keywords

CHOLERA VACCINE; ENTEROVACCINO; LAVANTUU TIROKOTE; MUTACOL; NEOTYF; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; TYFOID; TYPBAR VI; TYPH VAX; TYPHERIX; TYPHOID VACCINE; VAX TYVI;

CHOLERA; CONSENSUS; DEVELOPING COUNTRY; DIARRHEA; DRUG SAFETY; ENDEMIC DISEASE; FEVER; HUMAN; INFECTION PREVENTION; RASH; REVIEW; SHIGELLOSIS; TYPHOID FEVER; VACCINATION; VOMITING;

BACTERIAL VACCINES; CHOLERA; CHOLERA VACCINES; DEVELOPING COUNTRIES; DYSENTERY, BACILLARY; HUMANS; IMMUNIZATION PROGRAMS; SHIGELLA VACCINES; TYPHOID FEVER;

SHIGELLA;

EID: 10344230918     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.12.1939     Document Type: Review

References (126)

1. WHO: Cholera 2002. Wkly Epidemiol. Rec. (2003) 78:269-276. Source for annual updates on cholera from the WHO.
2. SACK DA, SACK RB, NAIR GB, SIDDIQUE AK: Cholera. Lancet (2004) 363(9404):223-233. A comprehensive review of cholera.
3. WHO: Cholera vaccines: a new public health tool? (2002) Geneva, Switzerland. A recent document from the WHO with updated recommendations on the use of cholera vaccines.
4. HOLMGREN J, BERGQUIST C: Oral B subunit killed whole-cell cholera vaccine. In: New Generation Vaccines. Levine MM, Kaper JB, Liu MA, Rappuoli R, Good MF (Eds), Marcel Dekker, NY, USA (2004):499-510. A detailed source of information on killed oral cholera vaccines and mechanism of protection against disease.
5. MOSLEY WH: The role of immunity in cholera. A review of epidemiological and serological studies. Tex. Rep. Biol. Med. (1969) 27(Suppl. 1):227-241.
6. FINKELSTEIN RA: Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J. Immunol. (1962) 89:264-271.
7. LEVINE MM, NALIN DR, CRAIG JP et al.: Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. (1979) 73(1):3-9.
8. KOSSACZKA Z, SHILOACH J, JOHNSON V et al.: Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae 0139 capsular potysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. (2000) 68(9):5037-5043.
9. CLEMENS JD, SACK DA, HARRIS JR et al.: Held trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 335(8684):270-273. A large-scale, randomised, controlled trial of the Swedish cholera vaccine in Bangladesh demonstrating efficacy.
10. SANCHEZ JL, VASQUEZ B, BEGUE RE et al.: Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 344(8932):1273-1276. A randomised controlled trial that confirmed efficacy of the Swedish cholera vaccine in a Latin American population.
11. CLEMENS JD, STANTON BF, CHAKRABORTY J et al.: B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J. Infect. Dis. (1987) 155(1):79-85. A study of the safety and immunogenicity of the Swedish oral cholera vaccine in Bangladesh.
12. ERIKSSON K, KILANDER A, HAGBERG L, NORKRANS G, HOLMGREN J, CZERKINSKY C: Intestinal immune responsiveness in HIV-infected individuals. Adv. Exp. Med. Biol. (1995) 371B:1011-1014.
13. ORTIGAO-DE-SAMPAIO MB, SHATTOCK RJ, HAYES P et al.: Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS (1998) 12(14):F145-F150.
14. LEWIS DJ, GILKS CF, OJOO S et al.: Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS (1994) 8(6):779-785.
15. TRACK DD, CLEMENS JD, KE NT et al.: Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 349(9047):231-235. An efficacy trial of the Vietnamese oral cholera vaccine.
16. TRACH DD, CAM PD, KE NT et al.: Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. World Health Organ. (2002) 80(1):2-8. A study showing equivalence in safety and immunogenicity between the Swedish and Vietnamese killed oral cholera vaccine in adults and children.
17. LEVINE MM, KAPER JB, HERRINGTON D et al.: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (1988) 2(8609):467-470.
18. KAPER JB, TACKET CO: Attenuated Vibrio cholerae strains as live oral cholera vaccines and vectors. In: New Generation Vaccines. Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (Eds), Marcel Dekker, NY, USA (2004):511-517. A detailed source of information on the live oral cholera vaccines.
19. PERRY RT, PLOWE CV, KOUMARE B et al.: A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ. (1998) 76(1):63-71. An evaluation of CVD 103-HgR among HIV-infected individuals.
20. RICHIE EE, PUNJABI NH, SIDHARTA YY et al.: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 18(22):2399-2410. A randomised controlled trial showing poor protective efficacy of CVD 103-HgR in Indonesia.
21. CALAIN P, CHAINE JP, JOHNSON E et al.: Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine (2004) 22(19):2444-2451. A non-randomised study of CVD 103-HgR in Micronesia.
22. COHEN MB, GIANNELLA RA, BEAN J et al.: Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun. (2002) 70(4):1965-1970. A study showing safety, immunogenicity and protection against experimental challenge with V. cholerae O1 conferred by Peru-15 in North American volunteers.
23. TAYLOR DN, SANCHEZ JL, CASTRO JM et al.: Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect. Immun. (1999) 67(4):2030-2034.
24. TAYLOR DN, TACKET CO, LOSONSKY G et al.: Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Inject. Immun. (1997) 65(9):3852-3856.
25. TACKET CO, KOTLOFF KL, LOSONSKY G et al.: Volunteer studies investigating the safety and efficacy of live oral E1 Tor Vibrio cholerae O1 vaccine strain CVD 111. Am. J. Trop. Med. Hyg. (1997) 56(5):533-537.
26. VALLE E, LEDON T, CEDRE B et al.: Construction and characterization of a nonproliferative E1 Tor cholera vaccine candidate derived from strain 638. Infect. Immun. (2000) 68(11):6411-6418.
27. BENITEZ JA, GARCIA L, SILVA A et al.: Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease- defective E1 Tor strain as a cholera vaccine candidate. Infect. Immun. (1999) 67(2):539-545.
28. CRUMP JA, LUBY SP, MINTZ ED: The global burden of typhoid fever. Bull. World Health Organ. (2004) 82(5):346-352. Recent estimates on typhoid fever burden of disease.
29. EDELMAN R, LEVINE MM: Summary of an international workshop on typhoid fever. Rev. Infect. Dis. (1986) 8:329-349.
30. SINHA A, SAZAWAL S, KUMAR R et al.: Typhoid fever in children aged less than 5 years. Lancet (1999) 354(9180):734-737. Community-based typhoid fever surveillance showing high incidence of typhoid fever in children aged ≤ 5 years.
31. SAHA SK, BAQUI AH, HANIF M et al.: Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr. Infect. Dis. J. (2001) 20(5):521-524.
32. WAIN J, KIDGELL C: The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:423-430. A thorough review of worldwide S. Typhi MDR.
33. PARRY C: The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Vietnam. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:413-422.
34. BAHL R, SINHA A, POULOS C et al.: Costs-of-illness of typhoid fever in Indian urban slum community: implications for vaccination policy. J. Health Popul. Nutr. (2004) (In Press). First community-based data on typhoid fever cost of illness.
35. WHO: Background document: the diagnosis, treatment and prevention of typhoid fever. (2003) WHO/V&B/03.07. A detailed WHO document on typhoid fever.
36. KIDGELL C, REICHARD U, WAIN J et al.: Salmonella typhi, the causative agent of typhoid fever, is approximately 50,000 years old. Infect Genet Evol (2002) 2:39-45.
37. LEVINE MM: Typhoid fever vaccines. In: Vaccines (3rd ed.), Plotkin SA, Orenstein WA (Eds), WB Saunders Co., Philadelphia, PA, USA (1999). A thorough review of typhoid fever vaccines.
38. PASETTI MF, LEVINE MM, SZTEIN MB: Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine (2003) 21(5-6):401-418.
39. KLUGMAN KP, KOORNHOF HJ, ROBBINS JB, LE CAM NN: Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 14(5):435-438. First evidence of 3-year efficacy of the Vi polysaccharide vaccine.
40. MASTROENI P, MENAGER N: Development of acquired immunity to Salmonella. J. Med. Microbiol. (2003) 52(Pt 6):453-459.
41. KANTELE A: Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine (1990) 8(4):321-326.
42. IVANOFF B, LEVINE MM, LAMBERT PH: Vaccination against typhoid fever: present status. Bull. World Health Organ. (1994) 72(6):957-971.
43. BODHIDATTA L, TAYLOR DN, THISYAKORN U, ECHEVERRIA P: Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev. Infect. Dis. (1987) 9(4):841-845.
44. IMMUNIZATION ACTION COALITION: Vaccines and biologicals used in US and foreign markets. (2003) P5120. St. Paul, MN, USA.
45. FELIX A, PITT R: A new antigen of B. typhosus. Lancet (1934) 2:186-191.
46. ROBBINS JD, ROBBINS JB: Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. (1984) 150(3):436-449.
47. ACHARYA IL, LOWE CU, THAPA R et al.: Prevention of typhoid fever in Nepal with the Vi capsulai polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. (1987) 317(18):1101-1104. First randomised controlled trial with the Vi polysaccharide vaccine.
48. KLUGMAN KP, GILBERTSON IT, KOORNHOF HJ et al.: Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2(8569):1165-1169. Randomised controlled trial with Vi polysaccharide.
49. WANG ZG, ZHOU WZ, SHI J: Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi (1997) 18(1):26-29. Randomised controlled trial with Chinese Vi polysaccharide.
50. VANG HH, WU CG, XIE GZ et al.: Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull. World Health Organ. (2001) 79(7):625-631. Randomised controlled trial with Chinese Vi polysaccharide.
51. HESSEL L, DEBOIS H, FLETCHER M, DUMAS R: Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18(9);609-620.
52. WORLD HEALTH ORGANIZATION EXPERT COMMITTEE ON BIOLOGIC STANDARDIZATION: Requirements on Vi polysaccharide for typhoid. World Health Organ. Tech. Rep. Ser. (1993) 840:14-32.
53. MCGHEE JR, MESTECKY J, DERTZBAUGH MT, ELDRIDGE JH, HIRASAWA M, KIYONO H: The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 10:75-88.
54. DUPONT HL, HORNICK RB, SNYDER MJ, DAWKINS AT, HEINER GG, WOODWARD TE: Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull. World Health Organ. (1971) 44:667-672.
55. CHUTTANI CS, PRAKASH K, VERGESE A, GUPTA P, CHAWLA RK, GROVER V: Ineffectiveness of an oral killed typhoid vaccine in a field trial. Bull. World Health Organ. (2004) 48:754-755.
56. CHATFIELD S, ROBERTS M, LONDONO P, CROPLEY I, DOUCE G, DOUGAN G: The development of oral vaccines based on live attenuated Salmonella strains. FEMS Immunol. Med. Microbiol. (1993) 7:1-7.
57. GERMANIER R, FUER E: Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. (1975) 131(5):553-558.
58. LEVINE MM, TACKET CO, SZTEIN MB: Host-Salmonella interaction: human trials. Microbes Infect. (2001) 3(14-15):1271-1279.
59. WAHDAN MH, SERIE C, CERISIER Y, SALLAM S, GERMANIER R: A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J. Infect. Dis. (1982) 145(3):292-295.
60. LEVINE MM, FERRECCIO C, BLACK RE, GERMANIER R: Large-scale field trial of Ty21a, a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 1:1049-1052.
61. BLACK RE, LEVINE MM, FERRECCIO C et al.: Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine (1990) 8(1):81-84.
62. FERRECCIO C, LEVINE MM, RODRIGUEZ H, CONTRERAS R: Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. (1989) 159(4):766-769.
63. LEVINE M, FERRECCIO C, CRYZ SJ JR, ORTIZ E: Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in a randomized controlled field trial. Lancet (1990) 336:891-894. Randomised coatrolled trial with Ty21a vaccine in Chile.
64. SIMANJUNTAK CH, PALEOLOGO FP, PUNJABI NH et al.: Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 338(8774):1055-1059. Randomised controlled trial with Ty21a vaccine in Indonesia.
65. LEVlNE MM, FERRECCIO C, BLACK RE, TACKET CO, GERMANIER R: Progress in vaccines against typhoid fever. Rev. Infect. Dis. (1989) 11(Suppl.3):S552-S567.
66. LEVINE MM, BLACK RE, FERRECCIO C et al.: The efficacy of attenuated Salmonella typhi oral vaccine strain Ty21a evaluated in controlled field trials. In: Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference, Stockholm, 1985. Holmgren J, Lindberg A, Möllby R (Eds), Studentlitteratur, Lund, Sweden (1986):90-101.
67. BLACK R, LEVINE MM, YOUNG C et al.: Immunogenicity of Ty21a attenuated 'Salmonella typhi' given with sodium bicarbonate or in enteric-coated capsules. Dev. Biol. Stand (1983) 53:9-14.
68. LINDBERG AA: Glycoprotein conjugate vaccines. Vaccine (1999) 17(Suppl. 2):S28-S36.
69. SZU SC, TAYLOR DN, TROFA AC et al.: Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. (1994) 62(10):4440-4444.
70. LIN FY, HO VA, KHIEM HB et al.: The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. (2001) 344(17):1263-1269.
71. MAI NL, PHAN VB, VO AH et al.: Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. (2003) 349(14):1390-1391. Four-year protective effect of the first Vi conjugate vaccine.
72. GARMORY HS, BROWN KA, TITBALL RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. (2002) 26(4):339-353. An updated review of S, Typhi strains for vaccine candidates.
73. TACKET CO, SZTEIN MB, WASSERMAN SS et al.: Phase II clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Immun. (2000) 68:1196-1201.
74. TACKET CO, PASETTI MF, SZTEIN MB, LIVIO S, LEVINE MM: Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. (2004) 190(3):565-570.
75. HOHMANN EL, OLETTA CA, KILLEEN KP, MILLER SI: phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. (1996) 173(6):1408-1414.
76. TACKET CO, KELLY SM, SCHODEL F et al.: Safety and immunogenicity in humans of an attenuated Salmonella typhi vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the asd-balanced lethal vector system. Infect. Immun. (1997) 65:3381-3385.
77. HINDLE Z, CHATFIELD SN, PILLIMORE J, BENTLEY M, JOHNSON J, COSGROVE CA: Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. (2002) 70:3457-3467.
78. KOTLOFF KL, WINICKOFF JP, IVANOFF B et al.: Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. (1999) 77(8):651-666. A definitive review of the global burden of shigellosis.
79. THIEM V, SETHABUTR O, VON SEIDLEIN L et al.: Is shigellosis even more widespread than previously thought? IpaH detection in Nha Trang, Vietnam. J. Clin. Microbiol. (2004) (In Press).
80. BENNISH ML, HARRIS JR, WOJTYNIAK BJ, STRUELENS M: Death in shigellosis: incidence and risk factors in hospitalized patients. J. Infect. Dis. (1990) 161(3):500-506.
81. BENNISH ML: Potentially lethal complications of shigellosis. Rev. Infect. Dis. (1991) 13(Suppl. 4):319-324.
82. THORPE CM, SMITH WE, HURLEY BP, ACHESON DW: Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect. Immun. (2001) 69(10):6140-6147.
83. LINDBERG AA, HAEGGMAN S, KARLSSON K, PHUNG DC, DANG DT: The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA. Bull. World Health Organ. (1984) 62(4):597-606.
84. SZU S, ROBBINS JB, SCHNEERSON R, POZGAY V, CHU C: Polysaccharide-based conjugate vaccines for enteric bacterial infections: typhoid fever, notypoidal salmonellosis, shigellosis, cholera, Escherichia coli 0157. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):471-478. An excellent review of conjugate vaccines to protect against enteric organisms.
85. TALUKDER KA, DUTTA DK, SAFA A et al.: Altering trends in the dominance of Shigella flexneri serotypes and emergence of serologically atypical S. flexneri strains in Dhaka, Bangladesh. J. Clin. Microbiol. (2001) 39(10):3757-3759.
86. TALUKDER KA, ISLAM MA, DUTTA DK et al.: Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh. J. Clin. Microbiol. (2002) 40(7):2490-2497.
87. TALUKDER KA, ISLAM Z, ISLAM MA et al.: Phenotypic and genotypic characterization of provisional sero type Shigella flexneri 1c and clonal relationships with 1a and 1b strains isolated in Bangladesh. J. Clin. Microbiol. (2003) 41(1):110-117.
88. MEL DM, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull. World Health Organ. (1965) 32(5):647-655.
89. KOTLOFF KL, NATARO JP, LOSONSKY GA et al.: A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffr: clinical experience and implications for Shigella infectivity. Vaccine (1995) 13(16):1488-1494.
90. FERRECCIO C, PRADO V, OJEDA A, CAYYAZO M, ABREGO P, GUERS L et al.: Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. (1991) 134(6):614-627.
91. FORMAL SB, KENT TH, MAY HC, PALMER A, FALKOW S, LABREC EH: Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J. Bacteriol. (1966)92(1):17-22.
92. MEL DM, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 1. Immunization of mice against experimental Shigella infection. Bull. World Health Organ. (1965) 32(5):633-636.
93. MEL D, STANKOVIC N: Study on the streptomycin-dependent Shigella flexneri strain for oral vaccination against dysentery. Vojnosanit. Pregl. (1965) 22(6):381-387.
94. MEL DM, PAPO RG, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 2. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials. Bull. World Health Organ. (1965) 32(5):637-645.
95. MEL DM, ARSIC BL, NIKOLIC BD, RADOVANIC ML: Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull. World Health Organ. (1968) 39(3):375-380.
96. MEL DM, CVJETANOVIC B, FELSENFELD O: Studies on vaccination against bacillary dysentery. 5. Studies in Erythrocebus patas. Bull. World Health Organ. (1970) 43(3):431-437.
97. MEL D, GANGAROSA EJ, RADOVANOVIC ML, ARSIC BL, LITVINJENKO S: Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull. World Health Organ. (1971) 45(4):457-464.
98. MEL DM, ARSIC BL, RADOVANOVIC ML, LITVINJENKO SA: Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol. Acad. Sci. Hung (1974) 21(1-2):109-114.
99. ISTRATI G, ISTRATI M, MEITERT T, CIUFECO C: Genetic stability of the non-pathogenic and anti-infectious immunogenic character of some strains of Sh. flexneri 2a. Arch. Roum. Pathol. Exp. Microbiol. (1965) 24(4):867-874.
100. MEITERT T, PENCU E, CIUDIN L, TONCIU M: Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch. Roum. Pathol. Exp. Microbiol. (1984) 43(3-4):251-278.
101. TU G, CUI C, WANG J et al: Double-blind field trial of oral live F2a-Sonnei (FS) dysentery vaccine. J. Biol. Prod. (1999) 12(3):178-180.
102. COSTER TS, HOGE CW, VANDEVERG LL et al.: Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. (1999) 67(7):3437-3443.
103. KATZ DE, COSTER TS, WOLF MK et al.: Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun. (2004) 72(2):923-930.
104. KOTLOFF K, BARREY E, HALE T, SANSONETTI PJ: Overview of live vaccine strategies against Shigella. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):723-735. An excellent in-depth review of shigellosis vaccines.
105. HARTMAN AB, VENKATESAN MM: Construction of a stable attenuated Shigella sonnet DeltavirG vaccine strain, WKSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect. Immun. (1998) 66(9):4572-4576.
106. KOTLOFF KL, TAYLOR DN, SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnet live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. (2002) 70(4):2016-2021.
107. NORIEGA FR, LOSONSKY G, LAUDERBAUGH C, LIAO FM, WANG JY, LEVINE MM: Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect. Immun. (1996) 64(8):3055-3061.
108. NORIEGA FR, LOSONSKY G, WANG JY, FORMAL SB, LEVINE MM: Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. (1996) 64(1):23-27.
109. KOTLOFF KL, NORIEGA FR, SAMANDARI T et al.: Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. (2000) 68(3):1034-1039.
110. BARREY E, LEVINE MM: Multivalent Shigella/enterotoxigenic Escherichia coli vaccine. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):751-754.
111. NORIEGA FR, LIAO FM, MANEVAL DR, REN S, FORMAL SB, LEVINE MM: Strategy for cross-protection among Shigella flexneri serotypes. Infect. Immun. (1999) 67(2):782-788.
112. ROBBINS JB, SCHNEERSON R, ANDERSON P, SMITH DH: The 1996 Alben Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilia influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA (1996) 276(14):1181-1185.
113. TAYLOR DN, TROFA AC, SADOFF J et al.: Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. (1993) 61(9):3678-3687.
114. COHEN D, ASHKENAZI S, GREEN MS et al.: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 349(9046):155-159. Randomised controlled trial that showed protection against shigellosis by a conjugate vaccine.
115. POZSGAY V, CHU C, PANNELL L, WOLFE J, ROBBINS JB, SCHNEERSON R: Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA (1999) 96(9):5194-5197.
116. XU DQ, CISAR JO, AMBULOS JN JR, BURR DH, KOPECKO DJ: Molecular cloning and characterization of genes for Shigella sonnet form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. Infect. Immun. (2002) 70(8):4414-4423.
117. GUSTAFSON GL, GANDER JE: O beta-(N-acetyl-alpha-glucosamine-1-phosphoryl) serine in proteinase I from Dictyostelium discoideum. Methods Enzymol. (1984) 107:172-183.
118. EMSLIE KR, SLADE MB, WILLIAMS KL: From virus to vaccine: developments using the simple eukaryote, Dictyostelium discoideum. Trends Microbiol. (1995) 3(12):476-479.
119. YOUMANS AS, YOUMANS GP: Preparation and effect of different adjuvants on the immunogenic activity of mycobacterial ribosomal fraction. J. Bacteriol. (1967) 94(4):836-843.
120. LEVENSON VI, SUBBOTINA IUL, GOFMAN IL, IAROVAIA LM: Ribosomal dysentery vaccine. I. Method of production, physical and chemical properties. Zh. Mikrobiol. Epidemiol. Immunobiol. (1978) (3):60-65.
121. LEVENSON VI, BELKIN ZP, EGOROVA TP, LIUBINSKAIA MM, SAZYKINA S: The immunogenic and serological properties of the O-specific polysaccharide (L-hapten) in Shigella. Zh. Mikrobiol. Epidemiol. Immunobiol. (1991) (7):25-29.
122. LEVENSON VJ, EGOROVA TP: Effective stimulation of the mucosal immune response by parenteral vaccination with weak antigen associated with a nucleoprotein vehicle. Ann. NY Acad. Sci. (1994) 730:353-355.
123. LEVENSON VJ, MALLETT CP, HALE TL: Protection against local Shigella sonnet infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect. Immun. (1995) 63(7):2762-2765.
124. ORR N, ROBIN G, COHEN D, ARNON R, LOWELL GH: Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. (1993) 61(6):2390-2395.
125. FRIES LF, MONTEMARANO AD, MALLETT CP, TAYLOR DN, HALE TL, LOWELL GH: Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. (2001) 69(7):4545-4553.
126. WANG JY, NORIEGA FR, GALEN JE, BARRY E, LEVINE MM: Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect. Immun. (2000) 68(8):4647-4652.